Retatrutide in liver disease research shows remarkable reductions in hepatic fat. Clinical trials reveal triple GIP/GLP-1/glucagon receptor agonism resolve
Read more Retatrutide in Liver Disease Research: Evidence for Hepatic Fat Reduction
This comparative review examines retatrutide and tirzepatide, evaluating how retatrutide’s triple-receptor agonism (GLP-1, GIP, and glucagon) differs mecha
Read more Retatrutide vs. Tirzepatide: How Triple Agonism Compares to Dual Agonism
Retatrutide clinical trials evaluate a novel triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 and Phase 3 data demonst
Read more Retatrutide Clinical Trials: Human Evidence, Efficacy, and Safety Findings
A comprehensive scientific overview of Retatrutide (LY3437943), detailing its novel triple-receptor agonist mechanism across GLP-1, GIP, and GCGR, Phase 2